Pfizer, Merck Collaborations With NicOx Progressing
This article was originally published in The Pink Sheet Daily
You may also be interested in...
Pfizer Acquires TransTech RAGE Compounds
TransTech Pharma’s receptor for advanced glycation end products antagonists have potential to treat Alzheimer’s disease.
Pfizer Acquires TransTech RAGE Compounds
TransTech Pharma’s receptor for advanced glycation end products antagonists have potential to treat Alzheimer’s disease.
NicOx Expects To File NDA For Osteoarthritis Drug In 2009
The French company says it would need a partner to launch the drug, a potential competitor to Pfizer’s Celebrex.